Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults

INTRODUCTION: In DUET, etravirine (ETR) 200 mg bid had durable efficacy and a favourable safety profile versus placebo, both arms with an optimised background regimen (BR) including darunavir/ritonavir (DRV/r). TMC125IFD3002 (VIOLIN; NCT01422330) investigated ETR plus ARVs other than DRV/r. MATERIAL...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Int AIDS Soc
Asıl Yazarlar: Arathoon, Eduardo, Bhorat, Asad, Silaghi, Rodica, Crauwels, Herta, Lavreys, Ludo, Tambuyzer, Lotke, Vanveggel, Simon, Opsomer, Magda
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: International AIDS Society 2014
Konular:
Poster Sessions – Abstract P251
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4225395/
https://ncbi.nlm.nih.gov/pubmed/25397527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.17.4.19783
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller